Development of CDK2 and CDK5 Dual Degrader TMX‐2172

Cyclin‐dependent kinase 2 (CDK2) is a potential therapeutic target for the treatment of cancer. Development of CDK2 inhibitors has been extremely challenging as its ATP‐binding site shares high similarity with CDK1, a related kinase whose inhibition causes toxic effects. Here, we report the developm...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie International Edition 2020-08, Vol.59 (33), p.13865-13870
Main Authors: Teng, Mingxing, Jiang, Jie, He, Zhixiang, Kwiatkowski, Nicholas P., Donovan, Katherine A., Mills, Caitlin E., Victor, Chiara, Hatcher, John M., Fischer, Eric S., Sorger, Peter K., Zhang, Tinghu, Gray, Nathanael S.
Format: Article
Language:English
Subjects:
Binding sites
Cancer
CDK2
CDK5
Cell cycle
Cell Division - drug effects
Cell Line, Tumor
Cyclin-dependent kinase 2
Cyclin-Dependent Kinase 2 - antagonists & inhibitors
Cyclin-Dependent Kinase 2 - metabolism
Cyclin-dependent kinase 4
Cyclin-dependent kinase 5
Cyclin-Dependent Kinase 5 - antagonists & inhibitors
Cyclin-Dependent Kinase 5 - metabolism
Degradation
drug design
Drug Screening Assays, Antitumor
Female
Humans
Kinases
Ovarian cancer
Ovarian Neoplasms - enzymology
Ovarian Neoplasms - pathology
Phosphorylation
protein degradation
Protein Kinase Inhibitors - chemical synthesis
Protein Kinase Inhibitors - pharmacology
Selectivity
Toxicity
Transcription
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cyclin‐dependent kinase 2 (CDK2) is a potential therapeutic target for the treatment of cancer. Development of CDK2 inhibitors has been extremely challenging as its ATP‐binding site shares high similarity with CDK1, a related kinase whose inhibition causes toxic effects. Here, we report the development of TMX‐2172, a heterobifunctional CDK2 degrader with degradation selectivity for CDK2 and CDK5 over not only CDK1, but transcriptional CDKs (CDK7 and CDK9) and cell cycle CDKs (CDK4 and CDK6) as well. In addition, we demonstrate that antiproliferative activity in ovarian cancer cells (OVCAR8) depends on CDK2 degradation and correlates with high expression of cyclin E1 (CCNE1), which functions as a regulatory subunit of CDK2. Collectively, our work provides evidence that TMX‐2172 represents a lead for further development and that CDK2 degradation is a potentially valuable therapeutic strategy in ovarian and other cancers that overexpress CCNE1. Selective targeting of closely related members of the cyclin‐dependent kinase family remains difficult. Here, a heterobifunctional degrader molecule, TMX‐2172, is described. Dual degradation of CDK2 and CDK5 in OVCAR8 cells is achieved by reducing the binding affinity of the pyrimidine kinase inhibitor for CDK4, CDK6, CDK7, and CDK9, and by differential recognition between CDK2 and CDK1 mediated by the E3 ligase cereblon.
ISSN:1433-7851
1521-3773
DOI:10.1002/anie.202004087